The PSG BioAccelerator
At PSG Life Sciences, we’ve optimized the fractional model for the biotech sector. Our Fractional Bioaccelerator program embeds senior-level commercialization talent into your team, providing executive leadership, structure, and execution while building a scalable commercial foundation for growth or exit.
Strategic Leadership. Without the Full-Time Overhead.
Emerging biotech and therapeutics companies face a critical challenge, building commercial momentum without overextending limited resources. PSG Life Sciences bridges that gap with Fractional Commercial teams designed specifically for venture-backed life science startups, platform biotech companies, and investor portfolios seeking to accelerate growth, partnerships, and valuation.
Whether you need a full team or just an expert, we have you covered.
PSG BioAccelerator
Our BioAccelerator Program delivers a full fractional commercialization team. Integrating executive leadership, marketing, business development, and sales execution to rapidly transform scientific innovation into sustainable market growth.
Executive Support
Our Fractional Executive Support services embed seasoned commercial leaders into your organization to provide strategic direction, operational oversight, and hands-on execution. Driving focus, accountability, and growth without the cost of a full-time hire.
Marketing Execution
Our Fractional Marketing Execution Services provide life science companies with on-demand, expert marketing strategy and implementation. Delivering campaigns, content, and lead generation programs that accelerate visibility, engagement, and revenue growth.
Sales Execution
Our Sales Execution Services provide experienced, hands-on professionals who engage directly with your target customers. Driving qualified opportunities, accelerating deal flow, and converting strategy into measurable revenue growth.
Related Articles
CNS and Neurodegeneration Biomarkers: In This Market, Speed Is the Product
Ultra-sensitive multiplex immunoassay technology now detects low-abundance biomarkers in complex matrices like cerebrospinal fluid, enabling earlier-stage Alzheimer’s and neurodegenerative disease research that simply wasn’t possible a few years ago. p-Tau 217 went...
Next-Generation Sequencing: The Growth Moved. Did Your Sales Strategy Move With It?
NGS isn’t "next gen" anymore. The core sequencing instrument market is dominated by a small number of established platform vendors, and that’s not changing. If your growth strategy still depends on competing for that instrument-level attention, you’re fighting a...
Pharmacodynamic Biomarker Services: The Fastest Path to Revenue Isn’t the Biotech Sponsor
Biomarker-guided drug development is now structural, not a passing trend; pharma and biotech companies rely on PD biomarkers to select doses, prove mechanism of action, and stratify patients across oncology, immunology, neurology, and rare disease. If you provide...
Gene Editing and CRISPR Reagents: One Market, Two Very Different Sales Cycles
Genome editing is moving from a research tool into therapeutic development pipelines, and that shift is creating real, recurring demand for guide RNAs, delivery reagents, and validation kits. It’s also creating a commercial trap for reagent companies that don’t...
We cannot wait for the next wave of VC or PE money to solve commercial problems.
I've spent the last several months at life science conferences, dinners, and networking events, talking to founders, CEOs, and investors. And I keep hearing the same thing, just in different rooms. Investors are stuck with Portfolios they can't exit. Which means less...
The ROI of Fractional Commercial Leadership
The biggest advantage of fractional leadership is return on investment. Companies gain access to executives with decades of experience at a fraction of the cost of a full-time hire. Fractional leaders also bring: External perspective Industry networks Proven...
Ready to BioAccelerate?
Whether you’re preparing for Series B, launching your first product, or positioning for acquisition, PSG Life Sciences provides the senior-level commercialization leadership and infrastructure to help you get there, faster, smarter, and at a fraction of the cost.